



Mylan to Release 2018 Fourth Quarter and Full Year Results and 2019 Guidance on Feb. 26, 2019

February 11, 2019

HERTFORDSHIRE, England, and PITTSBURGH, Feb. 11, 2019 /PRNewswire/ -- Global pharmaceutical company [Mylan N.V.](#) (NASDAQ: MYL) today announced that it will release its fourth quarter and full year 2018 financial results, as well as its 2019 financial guidance, on Tuesday, Feb. 26, after the close of the U.S. financial markets. The company will also host a webcast at 5 p.m. ET on Feb. 26, to discuss the results and 2019 guidance.

The briefing can be accessed live by calling 855.493.3607 or 346.354.0950 for international callers (ID#: 9783018) or at the following address on the company's website: investor.mylan.com. A replay of the webcast also will be available on the website.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com. We routinely post information that may be important to investors on our website at investor.mylan.com.



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/mylan-to-release-2018-fourth-quarter-and-full-year-results-and-2019-guidance-on-feb-26-2019-300793140.html>

SOURCE Mylan N.V.

Christine Waller (Media), 724.514.1968, or Melissa Trombetta (Investors), 724.514.1813